diabetic macular oedema

News

In its decanting of the BRUNELLO trial of remigromig for diabetic macular oedema, MSD seems to have left observers contemplating a glass half empty.

News

MSD's return to the ophthalmology field has been charged up with a positive phase 3 trial of Wnt-targeted remigromig in diabetic macular oedema.

News

Ollin has followed its $100m Series A last year with a massive $330m second round that will fund phase 3 trials of its challenger to Roche's Vabysmo.

News

Boehringer has started a phase 2 trial of an oral therapy that could help people with diabetic macular oedema avoid regular injections into the eye.

News

Bayer has been given a leg up in the competitive market for VEGF therapies used to treat eye diseases with a new EU approval for Eylea 8mg.

News

The renaissance of Roche's refillable ophthalmic implant Susvimo has continued with FDA approval for use in patients with diabetic macular oedema.